Amedisys (NASDAQ:AMED) initiated with Outperform rating and $206 (14% upside) price target at Credit Suisse.
BeiGene (NASDAQ:BGNE) resumed with Overweight rating at Morgan Stanley.
Karyopharm Therapeutics (NASDAQ:KPTI) downgraded to Neutral with a $19 (1% upside) price target at Wedbush.
Syros Pharmaceuticals (NASDAQ:SYRS) downgraded to Neutral with a $9 (2% downside risk) price target at Wedbush.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.